Macomics
- Company typePrivate
- Founded2020
- HeadquartersEdinburgh, United Kingdom
- Headcount11–50
- GTM typeB2B
- OfferingServices
Macomics firmographics
Firmographics- Name
- Macomics
- Legal name
- Macomics Ltd
- Website
- https://macomics.com
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Where Macomics is headquartered
LocationHeadquarters
- HQ city
- Edinburgh
- HQ country
- United Kingdom
- HQ region
- Europe
Offices2 records
Markets served
Macomics business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Operations
Revenue model
- Pharma drug discovery collaborations and licensing: Macomics partners with global pharma under worldwide drug discovery collaboration agreements (exemplified by Ono Pharmaceutical): Macomics uses ENIGMAC to identify and characterise antibody candidates against a novel macrophage target; partner receives an exclusive option to license global rights for development and commercialization; Macomics receives an up-front payment, R&D funding, success-based milestone payments and tiered royalties on global net sales.
- Pre-clinical / clinical milestone and royalty economics: Future revenue contingent on partner-led progression through development, with success-based milestone payments and tiered royalties on net sales layered on top of upfront and R&D funding — typical biotech platform-partnering capital flow used to fund continued in-house R&D and pipeline expansion.
- Venture capital and grant equity financing: Pre-revenue biotech funded by venture and growth capital (Epidarex Capital led rounds; Scottish Enterprise via Scottish Investment Bank; Caribou Property Limited; LifeLink Ventures) — used to advance the in-house pipeline and platform rather than to support commercial product sales.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Pharma drug-discovery collaboration and licensing deal economics (quote-based) |
Go-to-market motion3 records
Distribution channels3 records
Marketing channels5 records
Macomics product offering
Product offeringCore offering
Macomics is a macrophage drug discovery company that uses its proprietary ENIGMAC™ platform to identify and validate disease-specific macrophage targets and generate therapeutic antibody (and small-molecule) candidates. Its lead clinical-stage asset, MACO355, is a first-in-class anti-pan-LILR monoclonal antibody for cancer in IND-enabling studies, and the platform is being extended into antifibrotic and neurodegeneration/neuroinflammation indications.
Product overview
Macomics operates a platform-plus-modules architecture anchored by its proprietary ENIGMAC™ Drug Discovery Platform. ENIGMAC integrates the Macrophage Atlas (one of the largest pan-disease and healthy-tissue macrophage RNA-seq collections globally) with CRISPRa/CRISPRi-based gene editing in iPSC-derived macrophages and microglia, plus proprietary human cell models, to support target identification, validation, and antibody discovery for disease-specific macrophage populations in oncology, fibrosis, neurodegeneration, and inflammation. On top of this platform, Macomics is progressing a modality-agnostic therapeutic pipeline of antibody and small molecule programs, with MACO355—a first-in-class ligand-blocking independent pan-LILR monoclonal antibody in IND-enabling studies for cancer—as its lead clinical candidate.
Differentiator
Problem solved
Functional benefit
Brands
- ENIGMAC: ENIGMAC is Macomics' proprietary macrophage drug discovery platform that integrates a Macrophage Atlas, gene editing of macrophages, and iPSC-derived macrophages to enable gene-to-function target validation for novel macrophage therapies.
Products and services
- ENIGMAC™ Drug Discovery Platform Proprietary platform integrating large-volume human datasets, custom iPSC-derived macrophage/microglia cell models and CRISPRa/CRISPRi gene editing in human macrophages to enable gene-to-function target identification, validation and antibody discovery for oncology, fibrotic, neurodegenerative and inflammatory diseases; licensed to pharma partners through worldwide drug discovery collaborations.
- Macrophage Atlas Integrated pan-disease and healthy-tissue macrophage RNA-seq dataset described as one of the largest globally, used as the bioinformatics foundation of the ENIGMAC platform for cross-disease target discovery and validation.
- MACO355 First-in-class ligand-blocking-independent anti-pan-LILR monoclonal antibody for cancer that re-programmes immune-suppressed macrophages, induces tumour cell phagocytosis and NK cell tumour kill, reverts M2 macrophage-mediated T-cell suppression in vitro and slows tumour growth in vivo; currently in CMC and IND-enabling studies as Macomics' lead clinical candidate.
- Macomics Therapeutic Pipeline Modality-agnostic portfolio of therapeutic antibody and small-molecule programmes focused on validated macrophage targets across cancer (prostate and other solid tumours), fibrotic diseases of the liver, lung and kidney, neurodegeneration and chronic inflammatory disorders, progressing toward the clinic.
- ENIGMAC™ Antifibrotic Therapy Programme Application of the ENIGMAC™ platform to discover macrophage-targeted therapeutics for fibrotic diseases of the liver, lung and kidney, supported by validated in vitro co-culture and ex vivo human disease models.
- ENIGMAC™ Neurodegeneration and Neuroinflammation Programme Application of the ENIGMAC™ platform to discover novel targets in microglia for neurodegenerative and neuroinflammatory diseases including Alzheimer's disease, multiple sclerosis and ALS/MND, using gene-editable iPSC-derived microglia and lipid-loading disease models.
Quantifiable outcome
- Lead programme MACO355 — non-ligand-blocking pan-LILR monoclonal antibody — was the only antibody tested head-to-head able to activate highly immune-suppressed macrophages, reverting M2 (TGFβ/IL-10/IL-4) macrophage-mediated suppression of T-cell activity in vitro and slowing tumour growth in vivo.
- +2 more outcomes
Companies that use Macomics
Customer profileSegments3 records
Ideal customer profiles3 records
Macomics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability1 record
Feature5 records
Macomics partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core, flagship and minor.
- Institute of Oncology Research (IOR, Switzerland)coreScientific collaboration announced 19 June 2024 between Macomics and Prof. Andrea Alimonti's laboratory at IOR (Bellinzona, Switzerland). The collaboration combines IOR's pioneering prostate cancer models and myeloid-derived suppressor cell expertise with Macomics' macrophage expertise to explore new modes of action for macrophage-targeted therapies in prostate cancer.
- IFOM (AIRC Institute of Molecular Oncology)coreScientific collaboration announced 13 May 2024 between Macomics and Prof. Massimiliano Pagani's laboratory at IFOM (Milan, Italy). The collaboration brings together T-cell biology, ex vivo tumour organoids and macrophage expertise to explore new modes of action for macrophage-targeted therapies and to test Macomics' novel drug candidates in complex human assay systems.
- Ono Pharmaceutical Co., Ltd.flagshipWorldwide drug discovery collaboration agreement announced March 2023. Macomics will identify and characterise antibody candidates against a novel macrophage target of interest in cancer using its ENIGMAC™ platform; Ono receives an exclusive option to license global rights for further development and commercialization. Macomics receives an up-front payment, R&D funding, success-based milestone payments and tiered royalties on global net sales.
- University of EdinburghflagshipMacomics is a spinout from the University of Edinburgh; co-founded in 2020 by University of Edinburgh researchers Prof. Jeffrey Pollard (MRC Centre for Reproductive Health) and Dr Luca Cassetta. The University of Edinburgh is also listed as an academic partner, providing access to intellectual property that has enabled the development and progression of Macomics' portfolio. Macomics' Edinburgh labs are co-located within the University's Roslin Innovation Centre.
- University of CambridgeflagshipListed as one of Macomics' four academic partners. Macomics operates its Cambridge R&D site on the Cambridge Science Park (Technopark); the partnership provides access to intellectual property and academic expertise that has enabled development of its portfolio.
- BioIndustry Association (BIA)minorMacomics is a member of the UK BioIndustry Association (BIA), whose logo appears on the company website; Macomics also attends BIA events such as the BIA Life Science Leadership Summit 2022.
Scale indicators8 records
Recent moves9 records
Expansion highlights8 records
Macomics competitors and assessment
Company assessmentDirect peers
- Alector: Alector develops immuno-neurology drugs targeting microglia and other myeloid cells for neurodegenerative diseases (Alzheimer's, Parkinson's, frontotemporal dementia). Highly comparable to Macomics given Macomics' recent ENIGMAC platform extension into neurodegeneration/neuroinflammation via gene-editable iPSC-derived microglia.
- Vigil Neuroscience: Vigil Neuroscience is a microglia-focused biotech developing antibody therapies for rare and common neurodegenerative diseases, including TREM2 agonists. Directly comparable to Macomics' microglia-targeted ENIGMAC platform programmes and to MACO355's macrophage-reprogramming approach.
- Bolt Biotherapeutics: Bolt Biotherapeutics developed immune-stimulating antibody conjugates that target tumour-associated macrophages and other myeloid cells, with programmes in oncology. Comparable to Macomics on the antibody modality, TAM targeting, and macrophage re-programming biology, though delivered via ISAC technology rather than macrophage gene editing.
Broad incumbents
- Innate Pharma: Innate Pharma is a clinical-stage immuno-oncology company with a broad pipeline of antibody-based innate immune cell engagers, including macrophage-targeting programmes. Larger and more diversified than Macomics, but operates in the same macrophage/innate immunity drug discovery space with antibody modalities.
- Compugen: Compugen is a clinical-stage therapeutic discovery company leveraging predictive computational platforms to identify novel drug targets in immuno-oncology, including myeloid/TAM-targeting antibodies. Comparable to Macomics as a platform-driven antibody discovery company targeting tumour-associated macrophages.
Emerging players
- Pionyr Immunotherapeutics: Pionyr (acquired by AstraZeneca in 2023) developed antibody therapies targeting myeloid immune cells (TREM2, Dectin-2) in the tumour microenvironment. Highly comparable mechanism to Macomics' macrophage-targeting approach and illustrates a credible acquisition exit pathway for the asset class.
- Dren Bio: Dren Bio is a privately held biotech developing antibody-based myeloid engagers and other bispecifics for cancer and autoimmune disease. Comparable to Macomics in antibody-based myeloid/macrophage-directed drug discovery and operates as a similarly sized private biotech with pharma partnering potential.
- Myeloid Therapeutics: Myeloid Therapeutics is a clinical-stage immuno-oncology company developing myeloid cell-directed therapies including in vivo reprogramming of myeloid cells. Comparable to Macomics on the macrophage/myeloid reprogramming concept, though differentiated by in vivo cell engineering approach.
- MorphImmune (formerly AkesoBio): MorphImmune develops antibody-based therapies that target macrophage biology in cancer, including macrophage-engaging and reprogramming approaches. Directly comparable to Macomics' lead anti-pan-LILR antibody mechanism of macrophage re-programming in oncology.
- Carisma Therapeutics: Carisma Therapeutics is a clinical-stage biotech developing CAR-macrophage (CAR-M) cell therapies for solid tumours. Comparable to Macomics as a macrophage-focused immuno-oncology company, though differentiated by a cell therapy modality versus Macomics' antibody/small-molecule approach.
Market position
Strengths2 records
Competitive moat5 records
Key risks7 records
Key highlights7 records
Customer concentration
Macomics social profiles
Digital presenceMacomics compliance and trust
Trust signalCompliance1 record
Macomics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Macomics leadership team
Management profileNumber of profiles
Profiles7 records
Macomics funding detail
Funding detailFunding overview
Funding rounds3 records
Investors6 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Macomics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Macomics
What does Macomics do?
Macomics is a macrophage drug discovery company that uses its proprietary ENIGMAC™ platform to identify and validate disease-specific macrophage targets and generate therapeutic antibody (and small-molecule) candidates. Its lead clinical-stage asset, MACO355, is a first-in-class anti-pan-LILR monoclonal antibody for cancer in IND-enabling studies, and the platform is being extended into antifibrotic and neurodegeneration/neuroinflammation indications.
Is Macomics a public or private company?
Macomics is a private company. It is classified as venture growth investor backed and is currently operating.
When was Macomics founded?
Macomics was founded in 2020. It employs 11 to 50 people.
Where is Macomics based?
Macomics is headquartered in Edinburgh, United Kingdom, in the Europe region.
How does Macomics make money?
Three revenue lines are on record. Pharma drug discovery collaborations and licensing is the primary driver. The others are pre-clinical / clinical milestone and royalty economics and venture capital and grant equity financing.
Who are Macomics's main competitors?
Direct peers on record are Alector, Vigil Neuroscience and Bolt Biotherapeutics. Broad incumbents are Innate Pharma and Compugen. Emerging players are Pionyr Immunotherapeutics, Dren Bio, Myeloid Therapeutics, MorphImmune (formerly AkesoBio) and Carisma Therapeutics.
Does Macomics have an API?
No public API is recorded for Macomics.